Telpegfilgrastim Injection

DRUG4 trials

Sponsors

Xiamen Amoytop Biotech Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anhui Provincial Hospital

Conditions

AdolescentChemotherapy Induced NeutropeniaChemotherapy-induced NeutropeniaChildrenPreeclampsiaSolid Tumors

Phase 1

Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females

CompletedNCT06893796

Xiamen Amoytop Biotech Co., Ltd.Preeclampsia

Start: 2025-03-26End: 2025-05-08Updated: 2025-05-30

Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

CompletedNCT06924385

Xiamen Amoytop Biotech Co., Ltd.Preeclampsia

Start: 2025-04-06End: 2026-01-20Updated: 2026-04-13

Phase 2

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

RecruitingNCT06926751

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdolescent, Chemotherapy Induced Neutropenia, Children +1

Start: 2025-06-12End: 2027-09-01Target: 132Updated: 2026-05-07

Unknown Phase

Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor

RecruitingNCT07096479

Anhui Provincial HospitalChemotherapy-induced Neutropenia

Start: 2024-08-15End: 2025-08-15Target: 318Updated: 2025-07-31